<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>3-MeO-PCP - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/dissociatives/">Dissociatives</a> ‚Üí <span>3-MeO-PCP</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåÄ 3-MeO-PCP</h1>
        <h2 class="chemical-name">3-Methoxyphencyclidine</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="3-MeO-PCP" 
                data-category="Dissociatives" 
                data-chemical="3-Methoxyphencyclidine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>3-MeO-PCP</span> ‚Ä¢ <span>3-Methoxy-PCP</span> ‚Ä¢ <span>M-Hole</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>MeO</span> ‚Ä¢ <span>Three-MeO</span> ‚Ä¢ <span>Methoxy</span> ‚Ä¢ <span>Meta</span>
            </div>
            <div class="name-category">
              <h4>Research Chemical</h4>
              <span>3-MeO-Phencyclidine</span> ‚Ä¢ <span>3-Methoxy-1-(1-phenylcyclohexyl)piperidine</span>
            </div>
            <div class="name-category">
              <h4>Chemical Classification</h4>
              <span>Arylcyclohexylamine</span> ‚Ä¢ <span>NMDA antagonist</span> ‚Ä¢ <span>PCP analogue</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category dissociative-arylcyclohexylamine">Arylcyclohexylamine Dissociative</span>
          <span class="legal-status unscheduled">Unscheduled</span>
          <span class="duration long">4-8 hours</span>
          <span class="warning mania-risk">‚ö†Ô∏è Mania Risk</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/3-meo-pcp.jpg" alt="3-MeO-PCP white crystalline powder with molecular structure diagram showing methoxy substitution on phenyl ring" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇàH‚ÇÇ‚ÇáNO‚ÇÇ</p>
            <p>MW: 289.42 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure 3-MeO-PCP (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine powder, sometimes slightly chunky crystals</li>
            <li><strong>Odor:</strong> Virtually odorless when pure</li>
            <li><strong>Taste:</strong> Bitter, numbing to tongue and mouth</li>
            <li><strong>Solubility:</strong> Soluble in water, highly soluble in alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Research Chemical Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, white to off-white</li>
            <li><strong>Capsules:</strong> Pre-measured doses in gelatin caps</li>
            <li><strong>Pellets:</strong> Pressed tablets with exact dosing</li>
            <li><strong>Solution:</strong> Dissolved in ethanol or PG for volumetric dosing</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Issues</h4>
          <p><strong>Mislabeling:</strong> Often confused with 3-HO-PCP, 3-MeO-PCE</p>
          <p><strong>Impurities:</strong> Synthesis byproducts, unreacted precursors</p>
          <p><strong>Dosing errors:</strong> Extremely potent - milligram scales essential</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">1-3mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">3-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">5-10mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">10-15mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">15mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosage Considerations</h4>
        <ul>
          <li><strong>Extreme potency:</strong> Active in single-digit milligrams</li>
          <li><strong>Steep dose-response:</strong> 2-3mg difference = massive effect change</li>
          <li><strong>Individual sensitivity:</strong> Varies dramatically between users</li>
          <li><strong>Mania threshold:</strong> Higher doses significantly increase mania risk</li>
          <li><strong>No redosing:</strong> Long duration makes redosing extremely dangerous</li>
          <li><strong>Insufflation:</strong> 30-50% more potent than oral, faster onset</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> 3-MeO-PCP requires milligram-accurate scales. Eyeballing doses has resulted in hospitalizations and dangerous manic episodes.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:30</span>
          <span class="effect">Onset - dissociation begins, coordination affected</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-4:00</span>
          <span class="effect">Peak - full dissociative effects, potential mania</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained dissociation, cognitive effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-16:00</span>
          <span class="effect">Comedown - gradual return, residual stimulation</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Reported Positive Effects</h4>
          <ul>
            <li>Profound dissociation and ego dissolution</li>
            <li>Unique "hole" experiences at higher doses</li>
            <li>Pain relief and anesthetic effects</li>
            <li>Enhanced creativity and abstract thinking</li>
            <li>Euphoria and mood elevation</li>
            <li>Reduced social anxiety and inhibition</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <span class="danger-warning">‚ö†Ô∏è High Risk Profile</span>
          <h4>‚ùå Dangerous Effects</h4>
          <ul>
            <li><strong>Mania/psychosis:</strong> Grandiose delusions, reckless behavior</li>
            <li><strong>Motor impairment:</strong> Severe coordination loss</li>
            <li><strong>Amnesia:</strong> Complete memory blackouts</li>
            <li><strong>Compulsive redosing:</strong> Despite long duration</li>
            <li><strong>Hyperthermia:</strong> Dangerous overheating</li>
            <li><strong>Cardiovascular stress:</strong> Increased heart rate/blood pressure</li>
          </ul>
        </div>
      </div>

      <div class="mania-warning-section">
        <h4>üö® Mania Risk Profile</h4>
        <p>3-MeO-PCP has an unusually high propensity to induce manic episodes characterized by:</p>
        <ul>
          <li><strong>Grandiose delusions:</strong> Believing you have special powers or insights</li>
          <li><strong>Reckless behavior:</strong> Dangerous actions without considering consequences</li>
          <li><strong>Hypergraphia:</strong> Compulsive writing or drawing</li>
          <li><strong>Social disinhibition:</strong> Inappropriate social behavior</li>
          <li><strong>Insomnia:</strong> Complete inability to sleep for days</li>
          <li><strong>Paranoid ideation:</strong> Suspicious thoughts and conspiracy thinking</li>
        </ul>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>3-MeO-PCP is a potent non-competitive NMDA receptor antagonist in the arylcyclohexylamine class. It blocks the NMDA receptor ion channel, preventing glutamate and glycine binding, which disrupts normal excitatory neurotransmission. The methoxy substitution at the 3-position increases potency and duration compared to PCP while reducing some peripheral side effects.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptor</strong></span>
            <span class="affinity">High affinity antagonist (Ki: ~20 nM)</span>
            <span class="function">Primary dissociative effects, anesthesia, hole states</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Dopamine transporter (DAT)</strong></span>
            <span class="affinity">Moderate affinity (IC50: ~500 nM)</span>
            <span class="function">Dopaminergic stimulation, mania risk, euphoria</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin transporter (SERT)</strong></span>
            <span class="affinity">Weak-moderate affinity</span>
            <span class="function">Serotonergic effects, mood changes</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Norepinephrine transporter (NET)</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Stimulant effects, cardiovascular activation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Sigma-1 receptor</strong></span>
            <span class="affinity">Moderate agonist activity</span>
            <span class="function">Neuroprotection, cognitive effects, psychotomimetic effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Metabolism:</strong> Primarily hepatic via CYP450 enzymes, particularly CYP3A4</p>
          <p><strong>Half-life:</strong> 4-6 hours (effects last much longer due to active metabolites)</p>
          <p><strong>Bioavailability:</strong> ~85% oral, ~95% insufflated</p>
          <p><strong>Peak plasma:</strong> 1-2 hours oral, 30-60 minutes insufflated</p>
          <p><strong>Duration:</strong> 6-12 hours total effects, residual stimulation up to 16 hours</p>
          <p><strong>Metabolites:</strong> Several active metabolites contribute to prolonged effects</p>
        </div>

        <h4>Neurotoxicity & Safety Profile</h4>
        <div class="neurotoxicity-info">
          <p><strong>Olney's lesions:</strong> Potential for brain lesions similar to other NMDA antagonists</p>
          <p><strong>Dopaminergic effects:</strong> Monoamine transporter inhibition increases addiction potential</p>
          <p><strong>Cognitive impairment:</strong> Chronic use associated with memory and learning deficits</p>
          <p><strong>Bladder toxicity:</strong> Similar to ketamine, chronic use can cause cystitis</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Mania induction:</strong> Unusual propensity for manic episodes vs. other dissociatives</li>
          <li><strong>Stimulating dissociative:</strong> More activating than ketamine or DXM</li>
          <li><strong>Long duration:</strong> Effects persist much longer than many dissociatives</li>
          <li><strong>Hole potential:</strong> Can produce complete dissociative "hole" states</li>
          <li><strong>Cognitive persistence:</strong> Mental effects outlast physical dissociation</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Mania induction:</strong> High risk of dangerous manic episodes</li>
            <li><strong>Extreme potency:</strong> Overdose risk with small dosing errors</li>
            <li><strong>Motor impairment:</strong> Complete loss of coordination</li>
            <li><strong>Memory blackouts:</strong> Complete amnesia at higher doses</li>
            <li><strong>Compulsive behavior:</strong> Irresistible urge to redose</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Essential Precautions</h4>
          <ul>
            <li>Use milligram-accurate scale - NO EXCEPTIONS</li>
            <li>Have experienced, sober trip sitter present</li>
            <li>Remove access to more substance before dosing</li>
            <li>Avoid any physical activity or driving for 12+ hours</li>
            <li>Never combine with depressants or other dissociatives</li>
            <li>Start with threshold doses to assess sensitivity</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> History of mania/bipolar disorder, psychotic disorders, heart conditions, high blood pressure, seizure disorders, or are taking psychiatric medications. Extremely dangerous for those with mental health vulnerabilities.</p>
      </div>

      <div class="harm-reduction-specific">
        <h4>3-MeO-PCP Specific Harm Reduction</h4>
        <ul>
          <li><strong>Mania monitoring:</strong> Watch for grandiose thinking, reckless behavior</li>
          <li><strong>Physical safety:</strong> Remove potential hazards from environment</li>
          <li><strong>Communication:</strong> Avoid important decisions or communications while under influence</li>
          <li><strong>Hydration:</strong> Maintain fluid intake but avoid excessive water</li>
          <li><strong>Temperature:</strong> Monitor for hyperthermia, stay cool</li>
        </ul>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Extremely Dangerous</h4>
          <ul>
            <li><strong>CNS Depressants:</strong> Alcohol, benzodiazepines, opioids - risk of respiratory depression</li>
            <li><strong>Other dissociatives:</strong> Ketamine, DXM, PCP - unpredictable potentiation</li>
            <li><strong>MAOIs:</strong> Dangerous interaction with monoamine effects</li>
            <li><strong>Tramadol:</strong> Increased seizure risk, serotonin syndrome</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Stimulants:</strong> Increased cardiovascular strain, mania risk</li>
            <li><strong>Psychedelics:</strong> Unpredictable interactions, increased psychosis risk</li>
            <li><strong>Cannabis:</strong> May increase dissociation and confusion</li>
            <li><strong>Nitrous oxide:</strong> Risk of falls, dangerous impairment</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Extreme Caution</h4>
          <ul>
            <li><strong>Antidepressants:</strong> Potential for serotonin interactions</li>
            <li><strong>Anticonvulsants:</strong> May affect seizure threshold</li>
            <li><strong>Blood pressure medications:</strong> Cardiovascular interactions</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Unscheduled federally</strong> - However, many states have banned it. Some prosecutions under Federal Analogue Act due to PCP similarity.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Illegal under Psychoactive Substances Act 2016. Up to 5 years prison for possession.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá≥ China</h4>
            <p><strong>Controlled</strong> - Scheduled as controlled substance, affecting global supply of research chemicals.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Varies by country</strong> - Some EU countries have specifically banned, others rely on analogue laws.</p>
          </div>
        </div>
        
        <div class="legal-trends">
          <h4>‚öñÔ∏è Legal Trends</h4>
          <p>3-MeO-PCP is increasingly being banned worldwide due to reports of hospitalizations and dangerous behavior. The legal status is rapidly changing as authorities become aware of its risks.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1979</span>
          <p>First synthesized by medicinal chemists as part of PCP analogue research</p>
        </div>
        <div class="history-event">
          <span class="year">1999</span>
          <p>Appears in scientific literature studying NMDA receptor pharmacology</p>
        </div>
        <div class="history-event">
          <span class="year">2012</span>
          <p>Emerges on research chemical market as ketamine alternative</p>
        </div>
        <div class="history-event">
          <span class="year">2014-2016</span>
          <p>Reports of hospitalizations and manic episodes increase dramatically</p>
        </div>
        <div class="history-event">
          <span class="year">2016</span>
          <p>UK bans under Psychoactive Substances Act</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>China schedules, reducing global availability</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Research Chemical Culture</h4>
        <p>3-MeO-PCP gained notoriety in research chemical communities as a potent dissociative, but its reputation was quickly tarnished by reports of dangerous manic episodes and hospitalizations. It serves as a cautionary tale about the unpredictable nature of novel psychoactive substances.</p>
        
        <h4>Media Coverage</h4>
        <p>Unlike many research chemicals, 3-MeO-PCP received significant negative media attention due to several high-profile cases of users engaging in dangerous behavior while under its influence, leading to increased regulatory scrutiny.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>NMDA Receptor Studies</h4>
          <p>Limited research investigating its binding profile and selectivity at NMDA receptor subunits, primarily for understanding dissociative anesthesia mechanisms.</p>
        </div>
        
        <div class="research-item">
          <h4>Neurotoxicity Assessment</h4>
          <p>Ongoing studies examining potential for Olney's lesions and other forms of brain damage associated with chronic NMDA antagonist use.</p>
        </div>
        
        <div class="research-item">
          <h4>Mania Mechanisms</h4>
          <p>Research attempting to understand why 3-MeO-PCP has higher mania induction compared to other dissociatives, focusing on dopaminergic activity.</p>
        </div>
        
        <div class="research-item">
          <h4>Forensic Studies</h4>
          <p>Case studies documenting dangerous behaviors and medical emergencies associated with 3-MeO-PCP use for public health purposes.</p>
        </div>
      </div>

      <div class="research-limitations">
        <h4>üö´ Research Limitations</h4>
        <p>Due to its dangerous profile and lack of therapeutic potential, very little clinical research is being conducted. Most data comes from case reports of adverse events rather than controlled studies.</p>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Emergency & Safety Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Emergency Information</h4>
        <ul>
          <li><strong>Call emergency services immediately</strong> if experiencing mania or dangerous behavior</li>
          <li><a href="https://www.poison.org/">Poison Control</a> - 1-800-222-1222 (US)</li>
          <li><strong>Tell medical staff:</strong> "NMDA antagonist dissociative" for proper treatment</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction Resources</h4>
        <ul>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Comprehensive information</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Community harm reduction</li>
          <li><a href="https://tripsit.me/">TripSit</a> - Crisis support chat</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Research & Information</h4>
        <ul>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and warnings</li>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/">PubMed</a> - Scientific literature</li>
          <li><strong>Reddit communities:</strong> Often contain important safety warnings</li>
        </ul>
      </div>
    </div>
    
    <div class="final-warning">
      <h4>‚ö†Ô∏è Final Warning</h4>
      <p><strong>3-MeO-PCP is an extremely dangerous substance with a high risk of inducing mania, psychosis, and dangerous behavior. It has resulted in numerous hospitalizations and has no established therapeutic use. Consider safer alternatives for dissociative experiences, such as ketamine under medical supervision.</strong></p>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>